Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.42 |
| ▸ | PDE4A | P27815 | 6/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | F10 | P00742 | 3/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.37 |
| ▸ | F7 | P08709 | 3/20 | 0.37 |
| ▸ | F3 | P13726 | 3/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATF4 | P18848 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17888652 | 1.00 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CF2 | |
| SCHEMBL17931464 | 1.00 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CF2 | |
| SCHEMBL17899388 | 1.00 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CF2 | |
| SCHEMBL20525479 | 1.00 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CF2 | |
| SCHEMBL17888650 | 1.00 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CF2 | |
| SCHEMBL17888594 | 0.94 | PDE4D (0.37) | PDE4DPDE4APDE4BPDE4CF10 | |
| SCHEMBL17899128 | 0.94 | PDE4D (0.37) | PDE4DPDE4APDE4BPDE4CF10 | |
| SCHEMBL17888597 | 0.94 | PDE4D (0.37) | PDE4DPDE4APDE4BPDE4CF10 | |
| SCHEMBL17888612 | 0.86 | PDE4D (0.39) | PDE4DPDE4APDE4BPDE4CF10 | |
| SCHEMBL17899129 | 0.86 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013728-B2 | Cyclin-dependent kinase 8 and/or 19 inhibitor | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20210100783-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2021-04-08 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040329-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2016-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | SOST, BMP2, ALPI | PDE4D 3319/4885PDE4A 3148/4885PDE4B 2443/4885 |
| US-20210100783-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | CCNI, CDK9, CDK8 | PDE4D 2704/4885PDE4A 2562/4885PDE4B 2389/4885 |
| US-11013728-B2 | Cyclin-dependent kinase 8 and/or 19 inhibitor | CCNI, CDK9, CDKN1A | PDE4D 2725/4885PDE4A 2485/4885PDE4B 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.